A growth hormone-secreting pituitary adenoma presents substantial diagnostic and therapeutic challenges in clinical neuroendocrinology. While autonomous growth hormone hypersecretion classically manifests as acromegaly, many patients simultaneously exhibit hyperprolactinemia. This dual hormonal elevation frequently complicates diagnostic differentiation and subsequent management. Historically, endocrinologists and pathologists classified these neoplasms using simplistic immunohistochemical hormone staining. However, the 2022 World Health Organization classification of pituitary neuroendocrine tumors revolutionized this framework by prioritizing cell lineages and transcription factors. Furthermore, a landmark study of 810 patients provides vital clinical insights into the behavior of these complex neoplasms. Therefore, understanding these clinicopathological nuances enables clinicians to anticipate local tumor aggressiveness and refine post-surgical surveillance.

Clinical Presentation of Growth Hormone-Secreting Pituitary Adenoma

Patients with a growth hormone-secreting pituitary adenoma accompanied by hyperprolactinemia present with distinctive clinical features compared to normoprolactinemic cohorts. Notably, hyperprolactinemia prompts earlier clinical attention because affected individuals frequently develop overt symptoms such as galactorrhea, amenorrhea, and diminished libido. In contrast, isolated acromegaly typically progresses insidiously over several years without dramatic acute signs. Furthermore, individuals with dual hormone elevations display significantly higher baseline serum growth hormone concentrations. This pronounced endocrine burden correlates directly with serious structural mass effects. Specifically, neuro-ophthalmic evaluations reveal a markedly higher frequency of visual acuity loss and bitemporal hemianopia. Suprasellar extension frequently causes severe optic chiasm compression, which necessitates prompt surgical decompression. Although patients experience more pronounced visual impairments, these dramatic manifestations paradoxically lead to earlier clinical diagnosis. Clinicians should maintain heightened diagnostic suspicion whenever young patients present with unexplained galactorrhea or visual defects. Therefore, comprehensive diagnostic workups must evaluate both serum prolactin and growth hormone dynamics. Recognizing these dual features ensures timely neurosurgical referral and prevents permanent optic nerve injury.

Mechanisms Driving Concomitant Hyperprolactinemia

Clinicians must distinguish between true neoplastic co-secretion and the stalk effect when evaluating hyperprolactinemia in somatotroph tumors. Pituitary stalk compression obstructs normal hypothalamic dopamine transport, which subsequently disinhibits prolactin release from non-tumoral lactotrophs. In contrast, authentic co-secretion arises directly from neoplastic cells possessing dual secretory capacity within the PIT-1 transcription factor lineage. Because PIT-1 directs the development of both somatotrophs and lactotrophs, transformed cells frequently manufacture both hormones simultaneously. Consequently, mammosomatotroph and plurihormonal tumors actively produce both growth hormone and prolactin. A detailed analysis of 810 patients demonstrated that the hyperprolactinemic group presented with significantly larger tumor volumes than the normoprolactinemic group. Moreover, these larger tumors exhibited more severe cavernous sinus invasion alongside substantial suprasellar expansion. Bulky macroadenomas inevitably compress the infundibulum while simultaneously harboring elevated numbers of secreting neoplastic cells. Therefore, clinicians frequently encounter a synergistic mechanism involving both anatomical stalk compromise and autonomous tumoral secretion. Accurate post-surgical immunohistochemical examination confirms the underlying etiology. Accordingly, this differentiation prevents treating invasive somatotroph tumors with dopamine agonist monotherapy inappropriately.

Pathological Subtyping Under the 2022 WHO Classification

The 2022 World Health Organization classification updated pituitary tumor pathology by mandating lineage-specific transcription factor evaluation. Under this modern framework, somatotroph neoplasms segregate into biologically distinct entities. In the 810-patient cohort, sparsely granulated somatotroph tumors represented the most frequent subtype, comprising 46.19% of all cases. Additionally, plurihormonal pituitary neuroendocrine tumors accounted for 17.80%, while mammosomatotroph tumors constituted 17.37%. Notably, tumors from patients presenting with hyperprolactinemia displayed a significantly higher proportion of mammosomatotroph histology. Mammosomatotroph neoplasms possess dense secretory granules containing both hormones and exhibit robust nuclear PIT-1 immunoreactivity. In contrast, sparsely granulated variants characteristically exhibit cytokeratin fibrous bodies and show reduced somatostatin receptor expression. Pathologists now combine pituitary transcription factors, including PIT-1, TPIT, and SF-1, with routine hormonal biomarkers. Consequently, this detailed profiling replaces outdated histological descriptions with precise molecular taxonomies. Furthermore, accurate lineage assignment provides crucial biological information that directly informs subsequent medical management. Thus, comprehensive immunohistochemical typing serves as an indispensable tool for establishing individualized prognosis.

Tumor Invasiveness and Surgical Remission Rates

Transsphenoidal surgery remains the primary therapeutic intervention for growth hormone-secreting lesions. However, tumors presenting with concomitant hyperprolactinemia often display heightened local invasiveness on preoperative magnetic resonance imaging. Radiologists frequently identify extensive cavernous sinus invasion with internal carotid artery encasement, corresponding to elevated Knosp grades. Despite these anatomical challenges and larger tumor volumes, hyperprolactinemia does not significantly decrease biochemical remission rates. Neurosurgeons achieve equivalent postoperative hormonal normalization across both hyperprolactinemic and normoprolactinemic groups. This encouraging finding demonstrates that surgical debulking and curative resection remain achievable despite substantial lesion volume, provided skilled pituitary surgeons intervene. Complete excision of accessible tumor tissue and optic chiasm decompression promptly relieve neurological symptoms and lower hormonal burdens. Nevertheless, incomplete resection occurs frequently in widely invasive macroadenomas. Achieving biochemical remission requires normalized age-adjusted insulin-like growth factor 1 levels alongside suppressed nadir growth hormone. Consequently, severe anatomical invasion should not discourage teams from pursuing definitive surgical intervention. In addition, meticulous resection directly mitigates the risk of progressive neurological deficits.

Prognostic Significance of Immature PIT-1 Lineages and Therapeutic Strategies

Although hyperprolactinemia alone does not impair biochemical remission, underlying histopathological lineage powerfully influences long-term clinical outcomes. Most notably, immature PIT-1 lineage tumors exhibit highly aggressive clinical behavior. Patients with immature PIT-1 lineage neoplasms experience the lowest biochemical remission rates and the highest tumor recurrence rates. These tumors, previously recognized as silent subtype 3 adenomas, show marked cellular atypia and extensive dural invasion. Similarly, sparsely granulated somatotroph tumors correlate with less favorable outcomes and demonstrate resistance to first-generation somatostatin analogs. Therefore, pathological subtype serves as the primary determinant of long-term prognosis. In persistent or recurrent disease, multidisciplinary teams must deploy tailored medical regimens. While first-generation somatostatin analogs remain standard, mammosomatotroph lesions often respond favorably to dopamine agonists like cabergoline. For aggressive refractory tumors, pasireotide or the growth hormone receptor antagonist pegvisomant provides essential secondary control. Furthermore, stereotactic radiosurgery addresses residual cavernous sinus disease effectively. As a result, integrating pathological risk assessment into clinical workflows ensures timely therapeutic escalation and optimizes long-term survival.

Frequently Asked Questions

How does hyperprolactinemia affect biochemical remission in GHPA?

Hyperprolactinemia does not significantly decrease overall biochemical remission rates following transsphenoidal surgery. Although tumors presenting with hyperprolactinemia demonstrate greater local invasiveness and larger volumes, complete hormonal control largely depends on lineage cytopathology rather than serum prolactin elevations alone. Therefore, surgical resectability remains achievable when experienced neurosurgeons resect these complex lesions.

Why do patients with co-secreted prolactin present earlier?

Patients frequently present earlier because elevated prolactin causes overt symptomatic disturbances, specifically galactorrhea and gonadal dysfunction. In addition, suprasellar tumor expansion triggers noticeable visual field defects through chiasmatic compression. Consequently, these striking clinical symptoms prompt earlier specialist referral compared to the insidious, slowly progressive skeletal changes characteristic of isolated acromegaly.

Which PitNET subtype carries the highest risk of recurrence?

Immature PIT-1 lineage pituitary neuroendocrine tumors carry the highest recurrence risk and lowest biochemical remission rate. These aggressive neoplasms, previously recognized as silent subtype 3 adenomas, display persistent structural invasiveness and marked cellular atypia. Clinicians must monitor these patients intensively through routine neuroimaging and comprehensive endocrine evaluation to detect early relapse.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Mo C et al. Clinical characteristics and pathological features of growth hormone-secreting pituitary adenoma combined with hyperprolactinemia. J Neurooncol. 2025 Aug. doi: 10.1007/s11060-025-05041-w. PMID: 40266500.
2. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33(1):6-26.
3. Casar-Borota O. The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors. Brain Pathol. 2025;35(1):e13302.